Thrombosis and Disseminated Intravascular Coagulation following Treatment with the Prothrombin Complex Concentrate, DEFIX

Thromb Haemost 1999; 81(04): 667
DOI: 10.1055/s-0037-1614549

Letters to the Editor

Schattauer GmbH

P. H. Roddie

¹From the Dept. of Haematology, Royal Infirmary of Edinburgh, Edinburgh, UK

,

C. Stirling

¹From the Dept. of Haematology, Royal Infirmary of Edinburgh, Edinburgh, UK

,

E. E. Mayne

¹From the Dept. of Haematology, Royal Infirmary of Edinburgh, Edinburgh, UK

,

C. A. Ludlam

¹From the Dept. of Haematology, Royal Infirmary of Edinburgh, Edinburgh, UK

References
1 BCSH guidelines on oral anticoagulation: third edition. Br J Haematol. 1998; 101: 374-87.
2 Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR. Preston EF.Emergency oral anticoagulant reversal: the relative efficacy of infusions offresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-80.
3 Lusher JM. Prediction and management of adverse events associated withthe use of factor IX complex concentrates. Semin Hematol 1993; 30: 36-40.
4 Prowse CV, Cash JD. The use of factor IX concentrates in man: a 9-year experience of Scottish concentrates in the South-East of Scotland. Br J Haematol 1981; 47: 91-104.
5 McNeill SA, Ewing JC, Wallace WA, Stewart LH. Venous infarction of atesticle following factor IX concentrate (DEFIX) [letter]. Br J Haematol 1998; 101-210.